Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028

Report
78 Pages
October 2021
Region: Global
Kuick Research
ID: 5459357

Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028 Report Analysis & Data Highlights:

Rybrevant Patent Insight
Rybrevant Dosage & Price
Rybrevant Sales Forecast 2028: > USD 4 Billion
Rybrevant Role in NSCLC & Other Cancer Therapies
Rybrevant Structure & Pharmacokinetics Properties
Rybrevant Ongoing Clinical Trials: > 5 Clinical Studies
Rybrevant Reimbursement Scenario

The development of bispecific antibodies represents one of the most promising successes in cancer targeted therapy research and development. Bispecific antibodies are dual targeting modalities which can simultaneously combine two epitopes. Their novel dual binding efficacy opens up a wide range of applications application which can be exploited in redirecting T-cells, blocking two different signaling pathways, dual targeting of different disease mediators and delivering payloads to targeted cells. Owing to their enhance specificity, they are considered as ideal therapeutic molecule for the management of multifactorial cancers.

Recently in 2021, a novel bispecific antibody Rybrevant (Amivantamab) was granted approval by US FDA. Rybrevant is an EGF and MET directed bispecific antibody, developed by Janssen Pharmaceutical which is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EFGR) exon 20 insertion mutations. Clinical trials have demonstrated that the novel drug has shown enhanced efficacy in comparison to previously approved MET and EFGR inhibitors. As of now, the drug has only gained approval in US. However, it has filed regulatory submissions in other regions including Europe, China, Japan, and other regions.

The approval of drug Rybrevant in early 2021 is thought to revolutionize the paradigm treatment of EFGR mutated non-small cell lung cancer. It is expected that in short span of time, the drug will constitute a major share in the lung cancer therapeutics owing to the single product approval targeting EFGR mutations. It is analyzed that the market will witness high compound annual growth rates to surpass US$ 4 Billion by 2028. Apart from this, the favorable reimbursement policies including Janssen Care Path will also boost the uptake of drug in the market. Furthermore, the subsequent years will see approval of Rybrevant in different regions, which will further boost the growth of market.

Apart from non-small cell lung cancer, the drug is also being evaluated in other cancers including adenoid cystic carcinoma (ACC), stomach cancer, esophageal cancers, and other solid tumors. In addition to this, investigators are also validating the role of drug in combination with carboplatin, lazertrinib, osimertinib, and others which aim to enhance the efficacy of the drug. As per our analysis, the future will see dominance of combinational therapy which is mainly due to its increased efficiency and enhance survival outcomes.

Scientists are constantly exploring the sector of bispecific antibodies. Their multifactorial approach in the management of diseases and their ability to pass through the blood brain barrier is gaining the interest of various researchers. Extensive efforts by research institutions and pharmaceutical sector are boosting the global bispecific antibody market. The major key players in the market are Amgen, Genmab, Eli Lilly, NovImmune, Sanofi, Roche, AstraZeneca, and several others. These have developed robust pipeline of bispecific antibodies which will compete with already approved bispecifics in market.

The transient shift towards sedentary lifestyle and the increase in uptake of smoking, alcohol and tobacco consumption will led to rise in prevalence of lung cancer which will further propel the market. Moreover, the rates at which conventional therapies are failing possess an unmet need for the novel targeted therapy in the management of cancer. Presently, US contributes to the major share in the market due to several factors such as increasing prevalence of cancer and the expected high sales of Rybrevant will drive the growth of the market during the forecasted period. Moreover, presence of top key players in this region as well as rising awareness and acceptance of novel therapies are also going to fuel the growth of the market in this region. Apart from this, other regions such Europe, Asia-Pacific and Japan are also expanding their markets to secure their position in the global market.

1. Rybrevant (Amivantamab-vmjw): Third Approved Bispecific Antibody 2021

1.1 Overview
1.2 Approval & Patent Insight

2. Rybrevant Dosage & Price Analysis3. Rybrevant - Structure, Description & Pharmacokinetics

4. Rybrevant Mechanism of Action

4.1 General Mechanism of Bispecific Antibodies
4.2 Rybrevant

5. Rybrevant Role in NSCLC6. Rybrevant Role in Other Cancers

7. Rybrevant - Supplementary Information

7.1 Adverse Drug Reactions
7.2 Application in Specific Population

8. Rybrevant Market Analysis

8.1 Current Market Scenario
8.2 Future Market Opportunity

9. Rybrevant Sales Forecast
10. Rybrevant Reimbursement Policy

11. Rybrevant Clinical Trials Insight

11.1 By Phase
11.2 By Development Status
11.3 By Region

12. Ongoing Research & Development

13. Companies Developing Similar Bispecific Antibodies

13.1 Ablynx
13.2 Adimab
13.3 Affimed Therapeutics
13.4 Amgen
13.5 AstraZeneca (MedImmune)
13.6 Chugai Pharmaceutical
13.7 Eli Lilly
13.8 EMD Serono
13.9 Emergent BioSolutions
13.10 Genentech
13.11 Genmab
13.12 Immunomedics
13.13 Jounce Therapeutics
13.14 MacroGenics
13.15 Merus
13.16 Neovii Biotech
13.17 NovImmune
13.18 OncoMed Pharmaceuticals
13.19 Pieris
13.20 Regeneron Pharmaceuticals
13.21 Roche
13.22 Sanofi

List of Figures

Figure 1-1: Rybrevant - Response Rate (%)
Figure 1-2: Rybrevant - FDA Breakthrough Designation & Approval Year
Figure 2-1: Rybrevant - Price for 7ml Supply & Price per Unit of 50mg/ml Intravenous Solution (US$), October’2021
Figure 2-2: Rybrevant - Recommended Dose Per Cycle by Body Weight (mg)
Figure 2-3: Rybrevant - Dose Reduction in Patients with Weight Less Than 80Kg (mg)
Figure 2-4: Rybrevant - Dose Reduction in Patients with Weight More Than 80Kg (mg)
Figure 2-5: Rybrevant - Cost of Single Treatment Cycle (US$), October’2021
Figure 2-6: Rybrevant - Cost of Annual Treatment (US$), October’2021
Figure 4-1: Bispecific Antibodies - General Mechanism of Action
Figure 4-2: Bispecific Antibodies: Pathways for Induction of Cytotoxicity
Figure 4-3: Rybrevant - Mechanism of Action
Figure 5-1: Global - Newly Diagnosed Cases & Deaths Related to Lung Cancer (Million), 2020
Figure 5-2: Global - Lung Cancer Incidence by Type (%), 2020
Figure 5-3: Impact of Rybrevant over the NSCLC Cells
Figure 6-1: Global - Newly Diagnosed ACC, Stomach & Esophageal Cancer Cases, 2028
Figure 6-2: Impact of Rybrevant on MET & EGFR Mutated Cancers
Figure 7-1: Rybrevant Associated Adverse Events
Figure 8-1: Global - Estimated EGFR Exon 20 Insertion Mutated NSCLC Population for Rybrevant, 2021-2028
Figure 8-2: Global - Rybrevant Market Opportunity by 1% Adaptation Rate in EGFR Exon 20 Insertion Mutated NSCLC (US$ Million), 2021 - 2028
Figure 8-3: Global - Rybrevant Market Opportunity by 2% Adaptation Rate in EGFR Exon 20 Insertion Mutated NSCLC (US$ Million), 2021 - 2028
Figure 8-4: Global - Rybrevant Market Opportunity by 3% Adaptation Rate in EGFR Exon 20 Insertion Mutated NSCLC (US$ Million), 2021 - 2028
Figure 8-5: Global - Rybrevant Market Opportunity by 4% Adaptation Rate in EGFR Exon 20 Insertion Mutated NSCLC (US$ Million), 2021 - 2028
Figure 8-6: Global - Rybrevant Market Opportunity by 5% Adaptation Rate in EGFR Exon 20 Insertion Mutated NSCLC (US$ Million), 2021 - 2028
Figure 8-7: Global - Estimated ACC Population for Rybrevant, 2021-2028
Figure 8-8: Global - Rybrevant Market Opportunity by 1% Adaptation Rate in ACC Patients (US$ Million), 2021 - 2028
Figure 8-9: Global - Rybrevant Market Opportunity by 2% Adaptation Rate in ACC Patients (US$ Million), 2021 - 2028
Figure 8-10: Global - Rybrevant Market Opportunity by 3% Adaptation Rate in ACC Patients (US$ Million), 2021 - 2028
Figure 8-11: Global - Rybrevant Market Opportunity by 4% Adaptation Rate in ACC Patients (US$ Million), 2021 - 2028
Figure 8-12: Global - Rybrevant Market Opportunity by 5% Adaptation Rate in ACC Patients (US$ Million), 2021 - 2028
Figure 8-13: Global - Rybrevant Market Opportunity by 6% Adaptation Rate in ACC Patients (US$ Billion), 2021 - 2028
Figure 8-14: Global - Rybrevant Market Opportunity by 7% Adaptation Rate in ACC Patients (US$ Billion), 2021 - 2028
Figure 8-15: Global - Rybrevant Market Opportunity by 8% Adaptation Rate in ACC Patients (US$ Billion), 2021 - 2028
Figure 8-16: Global - Rybrevant Market Opportunity by 9% Adaptation Rate in ACC Patients (US$ Million), 2021 - 2028
Figure 8-17: Global - Rybrevant Market Opportunity by 10% Adaptation Rate in ACC Patients (US$ Million), 2021 - 2028
Figure 6-1: Global - Newly Diagnosed Stomach & Esophageal Cancer Cases, 2028
Figure 9-1: Global - Rybrevant Sales Forecast (US$ Million), 2021-2028
Figure 9-2: US - Rybrevant Sales Forecast (US$ Million), 2021-2028
Figure 9-3: ROW - Rybrevant Sales Forecast (US$ Million), 2022-2028
Figure 10-1: Global - Rybrevant Maximum Coverage by Medicaid (US$), 2021
Figure 10-2: Global - Rybrevant Maximum Coverage by Private Insurance Coverage (US$), 2021
Figure 11-1: Global - Number of Rybrevant Related Clinical Trials by Phase, October’2021
Figure 11-2: Global - Rybrevant Related Clinical Trials by Phase (%), October’2021
Figure 11-3: Global - Number of Rybrevant Related Clinical Trials by Development Status, October’2021
Figure 11-4: Global - Number of Rybrevant Related Clinical Trials by Development Status (%), October’2021
Figure 11-5: Global - Number of Rybrevant Related Clinical Trials by Region, October’2021
Figure 12-1: Rybrevant Phase II Trial - Salivary Gland Cancer Study Initiation & Completion Year
Figure 12-2: Rybrevant Phase II Trial - Gastric & Esophageal Cancer Study Initiation & Completion Year
Figure 12-3: Rybrevant Phase II Combinational Trial - Amivantamab & Lazertinib Study Initiation & Completion Year
Figure 12-4: Rybrevant Phase III Combinational Trial - Amivantamab, Pemetrexed and Carboplatin Study Initiation & Completion Year
Figure 12-5: Rybrevant Phase I Combinational Trial - Amivantamab, Lazertinib, Carboplatin & Pemetrexed Study Initiation & Completion Year
Figure 13-1: Ablynx - Clinical Pipeline
Figure 13-2: Affimed Therapeutics - Clinical Pipeline
Figure 13-3: Amgen - Clinical Pipeline
Figure 13-4: EMD Serono - Clinical Pipeline
Figure 13-5: Emergent Bioscience - Clinical Pipeline
Figure 13-6: Genmab - Clinical Pipeline
Figure 13-7: Jounce Therapeutics - Clinical Pipeline
Figure 13-8: MacroGenics - Clinical Pipeline
Figure 13-9: Merus - Clinical Pipeline
Figure 13-10: Novimmune - Clinical Pipeline
Figure 13-11: OncoMed - Clinical Pipeline
Figure 13-12: Pieris Pharmaceuticals - Clinical Pipeline
Figure 13-13: Roche - Clinical Pipeline

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Ablynx
Adimab
Affimed Therapeutics
Amgen
AstraZeneca (MedImmune)
Chugai Pharmaceutical
Eli Lilly
EMD Serono
Emergent BioSolutions
Genentech
Genmab
Immunomedics
Jounce Therapeutics
MacroGenics
Merus
Neovii Biotech
NovImmune
OncoMed Pharmaceuticals
Pieris
Regeneron Pharmaceuticals
Roche
Sanofi

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€761EUR$800USD£641GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€1427EUR$1,500USD£1,202GBP

Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028 Report Analysis & Data Highlights:

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Reports

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029

Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029

Bispecific Antibodies Market by Mechanism of Action, Therapeutic Area, End-user - Global Forecast 2025-2030

Combination Antibody Therapy Market by Type, Indication, Route of Administration, Distribution Channel, End-Use - Global Forecast 2025-2030

Bispecific Antibodies for Cancer Market 2024-2028